This page lists the SEC filings reported by STONEPINE CAPITAL, L.P..
Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13G/A | 2014-01-10 | STONEPINE CAPITAL L P | BIOSPECIFICS TECHNOLOGIES CORP | 357,298 | 5.6% | EDGAR |
SC 13G | 2013-09-17 | STONEPINE CAPITAL L P | BIOSPECIFICS TECHNOLOGIES CORP | 322,668 | 5.1% | EDGAR |
SC 13G/A | 2013-08-07 | STONEPINE CAPITAL L P | Nile Therapeutics, Inc. | 2,111,300 | 4.7% | EDGAR |
SC 13G/A | 2013-02-14 | STONEPINE CAPITAL L P | Nile Therapeutics, Inc. | 4,123,500 | 9.2% | EDGAR |
SC 13G/A | 2012-05-04 | STONEPINE CAPITAL L P | Sucampo Pharmaceuticals, Inc. | 779,072 | 5.0% | EDGAR |
SC 13G/A | 2012-04-13 | STONEPINE CAPITAL L P | Sucampo Pharmaceuticals, Inc. | 992,000 | 6.3% | EDGAR |
SC 13G/A | 2012-02-15 | STONEPINE CAPITAL L P | Nile Therapeutics, Inc. | 5,400,000 | 10.0% | EDGAR |
SC 13G/A | 2012-02-07 | STONEPINE CAPITAL L P | Sucampo Pharmaceuticals, Inc. | 1,163,020 | 7.4% | EDGAR |
SC 13G | 2011-06-30 | STONEPINE CAPITAL L P | Nile Therapeutics, Inc. | 5,400,000 | 10.0% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.